Synthesis and immunosuppressive activity of novel prodigiosin derivatives

Journal of Medicinal Chemistry

Volumn 43, Issue 13, 2000, Pages 2557-2565

  D'Alessio, Roberto ^a   Bargiotti, Alberto ^a   Carlini, Orlando ^a   Colotta, Francesco ^a   Ferrari, Mario ^a   Gnocchi, Paola ^a   Isetta, Annamaria ^a   Mongelli, Nicola ^a   Motta, Pietro ^a   Rossi, Arsenia ^a   Rossi, Mario ^a   Tibolla, Marcello ^a   Vanotti, Ermes ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYLOXY 5 [(5 UNDECYL 2H PYRROL 2 YLIDENE)METHYL] 2,2' BI 1H PYRROLE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; JANUS KINASE; PNU 156804; PRODIGIOSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IMMUNOREGULATION; MOUSE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL SURVIVAL; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; PRODIGIOSIN; PYRROLES; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0034729730     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm001003p     Document Type: Article

References (47)

1. Sigal, H. N.; Dumont, F. J. Immunosuppression. In Fundamental Immunology; Paul, W. E., Ed.; Raven Press: New York, 1993; p 903.
2. Liu, J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol. Today 1993, 14, 290-5.
3. Gerber, D. A.; Bonham, C. A.; Thomson, A. W. Immunosuppressive Agents: Recent Developments in Molecular Action and Clinical Application. Transplantation Proc. 1998, 30, 1573-9. Mor, E.; Yussim, A.; Chodoff, L.; Schwartz. New Immunosuppressive Agents for Maintenance Therapy in Organ Transplantation. BioDrugs 1997, 8, 469-488. Singer, N. G.; Mccune, W. J. Update on immunosuppressive therapy. Curr. Opin. Rheumatol. 1998, 10, 169-73.
4. Gerber, D. A.; Bonham, C. A.; Thomson, A. W. Immunosuppressive Agents: Recent Developments in Molecular Action and Clinical Application. Transplantation Proc. 1998, 30, 1573-9. Mor, E.; Yussim, A.; Chodoff, L.; Schwartz. New Immunosuppressive Agents for Maintenance Therapy in Organ Transplantation. BioDrugs 1997, 8, 469-488. Singer, N. G.; Mccune, W. J. Update on immunosuppressive therapy. Curr. Opin. Rheumatol. 1998, 10, 169-73.
5. Gerber, D. A.; Bonham, C. A.; Thomson, A. W. Immunosuppressive Agents: Recent Developments in Molecular Action and Clinical Application. Transplantation Proc. 1998, 30, 1573-9. Mor, E.; Yussim, A.; Chodoff, L.; Schwartz. New Immunosuppressive Agents for Maintenance Therapy in Organ Transplantation. BioDrugs 1997, 8, 469-488. Singer, N. G.; Mccune, W. J. Update on immunosuppressive therapy. Curr. Opin. Rheumatol. 1998, 10, 169-73.
6. Keown, P. A.; Primmett, D. R. Cyclosporine: The principal immunosuppressant for renal transplantation. Transplantation Proc. 1998, 30, 1712-5. Resch, K.; Szamel, M. Molecular mechanism of the immunosuppressive action of cyclosporin A. Int. J. Immunopharmacol. 1998, 19, 579-85. Vanrenterghem, Y. Tacrolimus (FK 506) in kidney transplantation. Transplantation Proc. 1998, 30, 2171-3. Busuttil, R. W.; Holt, C. D. Tacrolimus is superior to cyclosporine in liver transplantation. Transplantation Proc. 1998, 30, 2174-8. Kahan, B. D. Emerging strategies for the clinical application of rapamycin. Clin. Biochem. 1998, 31, 341-4. Sehgal, S. N. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of Action Immunosuppressive Effect Results From Blockade of Signal Transduction and Inhibition of Cell Cycle Progression. Clin. Biochem. 1998, 31, 335-40.
7. Keown, P. A.; Primmett, D. R. Cyclosporine: The principal immunosuppressant for renal transplantation. Transplantation Proc. 1998, 30, 1712-5. Resch, K.; Szamel, M. Molecular mechanism of the immunosuppressive action of cyclosporin A. Int. J. Immunopharmacol. 1998, 19, 579-85. Vanrenterghem, Y. Tacrolimus (FK 506) in kidney transplantation. Transplantation Proc. 1998, 30, 2171-3. Busuttil, R. W.; Holt, C. D. Tacrolimus is superior to cyclosporine in liver transplantation. Transplantation Proc. 1998, 30, 2174-8. Kahan, B. D. Emerging strategies for the clinical application of rapamycin. Clin. Biochem. 1998, 31, 341-4. Sehgal, S. N. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of Action Immunosuppressive Effect Results From Blockade of Signal Transduction and Inhibition of Cell Cycle Progression. Clin. Biochem. 1998, 31, 335-40.
8. Keown, P. A.; Primmett, D. R. Cyclosporine: The principal immunosuppressant for renal transplantation. Transplantation Proc. 1998, 30, 1712-5. Resch, K.; Szamel, M. Molecular mechanism of the immunosuppressive action of cyclosporin A. Int. J. Immunopharmacol. 1998, 19, 579-85. Vanrenterghem, Y. Tacrolimus (FK 506) in kidney transplantation. Transplantation Proc. 1998, 30, 2171-3. Busuttil, R. W.; Holt, C. D. Tacrolimus is superior to cyclosporine in liver transplantation. Transplantation Proc. 1998, 30, 2174-8. Kahan, B. D. Emerging strategies for the clinical application of rapamycin. Clin. Biochem. 1998, 31, 341-4. Sehgal, S. N. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of Action Immunosuppressive Effect Results From Blockade of Signal Transduction and Inhibition of Cell Cycle Progression. Clin. Biochem. 1998, 31, 335-40.
9. Keown, P. A.; Primmett, D. R. Cyclosporine: The principal immunosuppressant for renal transplantation. Transplantation Proc. 1998, 30, 1712-5. Resch, K.; Szamel, M. Molecular mechanism of the immunosuppressive action of cyclosporin A. Int. J. Immunopharmacol. 1998, 19, 579-85. Vanrenterghem, Y. Tacrolimus (FK 506) in kidney transplantation. Transplantation Proc. 1998, 30, 2171-3. Busuttil, R. W.; Holt, C. D. Tacrolimus is superior to cyclosporine in liver transplantation. Transplantation Proc. 1998, 30, 2174-8. Kahan, B. D. Emerging strategies for the clinical application of rapamycin. Clin. Biochem. 1998, 31, 341-4. Sehgal, S. N. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of Action Immunosuppressive Effect Results From Blockade of Signal Transduction and Inhibition of Cell Cycle Progression. Clin. Biochem. 1998, 31, 335-40.
10. Keown, P. A.; Primmett, D. R. Cyclosporine: The principal immunosuppressant for renal transplantation. Transplantation Proc. 1998, 30, 1712-5. Resch, K.; Szamel, M. Molecular mechanism of the immunosuppressive action of cyclosporin A. Int. J. Immunopharmacol. 1998, 19, 579-85. Vanrenterghem, Y. Tacrolimus (FK 506) in kidney transplantation. Transplantation Proc. 1998, 30, 2171-3. Busuttil, R. W.; Holt, C. D. Tacrolimus is superior to cyclosporine in liver transplantation. Transplantation Proc. 1998, 30, 2174-8. Kahan, B. D. Emerging strategies for the clinical application of rapamycin. Clin. Biochem. 1998, 31, 341-4. Sehgal, S. N. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of Action Immunosuppressive Effect Results From Blockade of Signal Transduction and Inhibition of Cell Cycle Progression. Clin. Biochem. 1998, 31, 335-40.
11. Keown, P. A.; Primmett, D. R. Cyclosporine: The principal immunosuppressant for renal transplantation. Transplantation Proc. 1998, 30, 1712-5. Resch, K.; Szamel, M. Molecular mechanism of the immunosuppressive action of cyclosporin A. Int. J. Immunopharmacol. 1998, 19, 579-85. Vanrenterghem, Y. Tacrolimus (FK 506) in kidney transplantation. Transplantation Proc. 1998, 30, 2171-3. Busuttil, R. W.; Holt, C. D. Tacrolimus is superior to cyclosporine in liver transplantation. Transplantation Proc. 1998, 30, 2174-8. Kahan, B. D. Emerging strategies for the clinical application of rapamycin. Clin. Biochem. 1998, 31, 341-4. Sehgal, S. N. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of Action Immunosuppressive Effect Results From Blockade of Signal Transduction and Inhibition of Cell Cycle Progression. Clin. Biochem. 1998, 31, 335-40.
12. Vitale, A.; Foster, C. S. Immunosuppressive chemotherapy. Textb. Ocul. Pharmacol. 1997, 723-61. Tolkoff-Rubin, N., E.; Rubin, R. H. The purine antagonists: azathioprine and mycophenolate mofetil. Ther. Immunol. 1996, 44-56. Behrend M. Mycophenolate mofetil (Cellcept). Exp. Opin. Invest. Drugs 1998, 7, 1509-19.
13. Vitale, A.; Foster, C. S. Immunosuppressive chemotherapy. Textb. Ocul. Pharmacol. 1997, 723-61. Tolkoff-Rubin, N., E.; Rubin, R. H. The purine antagonists: azathioprine and mycophenolate mofetil. Ther. Immunol. 1996, 44-56. Behrend M. Mycophenolate mofetil (Cellcept). Exp. Opin. Invest. Drugs 1998, 7, 1509-19.
14. Vitale, A.; Foster, C. S. Immunosuppressive chemotherapy. Textb. Ocul. Pharmacol. 1997, 723-61. Tolkoff-Rubin, N., E.; Rubin, R. H. The purine antagonists: azathioprine and mycophenolate mofetil. Ther. Immunol. 1996, 44-56. Behrend M. Mycophenolate mofetil (Cellcept). Exp. Opin. Invest. Drugs 1998, 7, 1509-19.
15. Kahan, B. D.; Gibbons-Stubber, S.; Tejpal, N.; Chou T. C. Prospects for synergistic immunosuppressive drug therapy in the coming decade. Transplantation Proc. 1992 Aug, 24(4), 1263-5.
16. For an historical excursus on prodigiosins, see: Gaughran, E. R. L. From superstition to science: the hystory of a bacterium. Trans. N.Y. Acad. Sci. 1968, 3-24.
17. Wrede, F.; Rothhass, A. Z. Physiol. Chem. 1934, 226, 95. Thompson, P. E.; McCarthy, D. A.; Bayles, A.; Reinertson, J. W.; Cook, A. R. Antibiot. Chemother. 1956, 6, 337.
18. Wrede, F.; Rothhass, A. Z. Physiol. Chem. 1934, 226, 95. Thompson, P. E.; McCarthy, D. A.; Bayles, A.; Reinertson, J. W.; Cook, A. R. Antibiot. Chemother. 1956, 6, 337.
19. Harashima, K.; Tsuchida, N.; Tanaka, T.; Nagasatu, J. Agric. Biol. Chem. 1967, 31, 481-9.
20. Tsuji, R. F.; Yamamoto, M.; Nakamura, A.; Katoka, T.; Magae, J.; Nagai, K.; Jamasaki, M. Selective Immunosuppression of Prodigiosin 25-C and FK 506 in the Murine Immune System. J. Antibiot. 1990, 43, 1293-01. Lee, M.-H.; Yamashita, M.; Tsuji, R. F.; Yamasaki, M.; Kataoka, T.; Magae, J.; Nagai, K. Suppression of T Cell Stimulating Function of Allogeneic Antigen Presenting Cells by Prodigiosin 25-C. J. Antibiot. 1998, 51, 92-4.
21. Tsuji, R. F.; Yamamoto, M.; Nakamura, A.; Katoka, T.; Magae, J.; Nagai, K.; Jamasaki, M. Selective Immunosuppression of Prodigiosin 25-C and FK 506 in the Murine Immune System. J. Antibiot. 1990, 43, 1293-01. Lee, M.-H.; Yamashita, M.; Tsuji, R. F.; Yamasaki, M.; Kataoka, T.; Magae, J.; Nagai, K. Suppression of T Cell Stimulating Function of Allogeneic Antigen Presenting Cells by Prodigiosin 25-C. J. Antibiot. 1998, 51, 92-4.
22. Nakamura, A.; Nagai, K.; Ando, K.; Tamura, G. Selective Suppression by Prodigiosin of the Mitogenic Response of Murine Splenocytes. J. Antibiot. 1986, 39, 1155-9. Fürstner, A.; Szillat, H.; Gabor, B.; Mynott, R. Platinum- and Acid-Catalyzed Enyne Methatesis Reactions: Mechanistic Studies and Applications to the Syntheses of Streptorubin B and Metacycloprodigiosin. J. Am. Chem. Soc. 1998, 120, 8305-14.
23. Nakamura, A.; Nagai, K.; Ando, K.; Tamura, G. Selective Suppression by Prodigiosin of the Mitogenic Response of Murine Splenocytes. J. Antibiot. 1986, 39, 1155-9. Fürstner, A.; Szillat, H.; Gabor, B.; Mynott, R. Platinum- and Acid-Catalyzed Enyne Methatesis Reactions: Mechanistic Studies and Applications to the Syntheses of Streptorubin B and Metacycloprodigiosin. J. Am. Chem. Soc. 1998, 120, 8305-14.
24. Han, Sang Bae; Kim, Hwan Mook; Kim, Young Hee; Lee, Chang Woo; Jang, Eun-Sook; Son, Kwang Hee; Kim, Sung Uk; Kim, Young Kook. T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. Int. J. Immunopharmacol. 1998, 20, 1-13.
25. Gnocchi, P.; Fornasiero, M. C.; Saccardo, B.; Ferrari, M.; Musanti, R.; Miraglia, N.; Losa, C.; Mameli, M.; Magistrelli, M.; Colotta, F.; Isetta, A. M. PNU-156804, a new synthetic immunosuppressant, inhibits T-lymphocyte proliferation affecting IL-2 signal transduction. Signal transduction by JAKs and STATs Symposium, 3-8 February, 1998, Tamarron, CO.
26. For an overview on recent advances in JAK-3 inhibition see Sudbeck, E. A.; Uckun, F. M. Recent advances in JAK3 kinase inhibitors. IDrugs 1999, 2, 1026-30.
27. Rizzo, V.; Morelli, A.; Pinciroli, V.; Sciangula, D.; D'Alessio, R. Equilibrium and Kinetics of Rotamer Interconversion in Immunosuppressant Prodigiosin Derivative in Solution. J. Pharm. Sci. 1999, 88, 73-8.
28. (a) Rapoport, H.; Holden, K. G. The Synthesis of Prodigiosin. J. Am. Chem. Soc. 1962, 84, 635-42.
29. (b) Boger, D. L.; Patel, M. Total Synthesis of Prodigiosin Tetrahedron Lett. 1987, 28, 2499-502.
30. (c) Boger, D. L.; Patel, M. Total Synthesis of Prodigiosins, Prodigiosene and Desmethoxyprodigiosin: Diels-Alder Reactions of Heterocyclic Azadienes and Development of an Effective Palladiumd(II)-Promoted 2,2′-Bipyrrole Coupling Procedure. J. Org. Chem. 1988, 53, 1405-15.
31. (d) Wasserman, H. H.; Rodgers, G. C.; Keith, D. D. Undecylprodigiosin. Tetrahedron 1976, 32, 1851-4.
32. (e) Wasserman, H. H.; Lombardo, L. J. The Chemistry of Vicinal Tricarbonyls a total Synthesis of Prodigiosin. Tetrahedron Lett. 1989, 30, 1725-28.
33. (f) Blake, A. J.; Hunter, G. A.; McNab, H. A Short Synthesis of Prodigiosin Analogues. Chem. Commun. 1990, 734-6.
34. (g) Wasserman, H. H.; Petersen, A. K.; Xia, M.; Wang, J. Pyrrole-singlet oxygen reactions leading to α,α′-bipyrroles. Synthesis of prodigiosin and analogues. Tetrahedron Lett. 1999, 40, 7587-89.
35. This assembly sequence was recently adopted for the synthesis of nonylprodigiosin: Fürstner, A.; Grabowski, J.; Lehmann, C. W. Total Synthesis and Structural Refinement of the Cyclic Tripyrrole Pigment Nonylprodigiosin. J. Org. Chem. 1999, 64, 8275-80.
36. D'Alessio, R.; Rossi, A. Short synthesis of undecylprodigiosine. A new route to 2,2′-bipyrrolyl-pyrromethene systems. Synlett 1996, 6, 513-4.
37. Due, L.; McGarrity, J. F.; Meul, T.; Warm, A. Methyl (E)-4-Chloro-3-methoxy-2-butenoate: An Extremely Versatile Four Carbon Building Block. Synthesis 1992, 391-4.
38. D'Alessio, R.; Rossi, A.; Tibolla, M.; Ceriani, L. (Pharmacia & Upjohn). Process for the preparation of 2,2′-bipyrrolyl-pyrromethene (Prodigiosins) derivatives. PCT WO 97/30029 (1997).
39. 3 containing 10% of NaCl was added and the product extracted with dichloromethane. The crude product was chromatographed on silica gel eluting with n-hexane/ethyl acetate 2:1. The desired compound 5 was obtained in 17% yield together with about 40% of the unreacted pyrrolinone derived from the hydrolysis of the corresponding starting triflate.
40. O-Methylation (tetramethylnaphthalendiamine/trimethyloxonium tetrafluoroborate); oxidation of methyl to carboxy (lead tetraacetate/acetic acid, silver nitrate); amidation (oxalyl chloride, ethylamine); hydrolysis and thermal decarboxylation (220 °C) of the 2-carboethoxy group.
41. Albers-Schönberg, G.; Arison, B. H.; Hensens, O. D.; Hirshfield, J.; Hoogsteen, K.; Kaczka, E. A.; Rhodes, R. E.; Kahan, J. S.; Kahan, F. M.; Ratcliffe, R. W.; Wallon, E.; Ruswinkle, L. J.; Morin, R. B.; Christensen, B. G. Structure and Absolute Configuration of Thienamycin. J. Am. Chem. Soc. 1978, 100, 6491-8.
42. Rapoport, H.; Castagnoli, N., Jr. 2,2′-Bipyrrole. J. Am. Chem. Soc. 1962, 84, 2178-81.
43. Deol, B. S.; Alden, J. R.; Still, J. L.; Robertson, A. V.; Winkler, J. Isolation and Structure Confirmation of Norprodigiosin from a Serratia Marcescens Mutant. Aust. J. Chem. 1974, 27, 2657-62.
44. Mortellaro, A.; Songia, S.; Gnocchi, P.; Ferrari, M.; Fornasiero, C.; D'Alessio, R.; Isetta, A.; Colotta, F.; Golay, J. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kB and AP-1 activation. J. Immunol. 1999, 162, 7102-9.
45. Martina, S.; Enkelmann, V.; Wegner, G.; Schlüter, A. D. N-Protected Pyrrole Derivatives Substituted for Metal-Catalyzed Cross-Coupling Reactions. Synthesis 1991, 613-5.
46. Johnson, C. N.; Stemp, G.; Anand, N.; Stephen, S. C.; Gallagher, T. Palladium (0)-Catalysed Arylations using Pyrrole and Indole 2-Boronic Acids. Synlett 1998, 1025-7.
47. Ferrari, M.; Fornasiero, M. C.; Isetta, A. M. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J. Immunol. Methods 1990, 131 (2), 165-72.